{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:42:14Z","timestamp":1793727734151,"version":"4.6.1"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.critrevonc.2025.105046","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T16:52:59Z","timestamp":1764694379000},"page":"105046","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["HER2 in gynecological malignancies: Bridging the gap between standardized pathological assessment and precision therapy"],"prefix":"10.1016","volume":"218","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4473-7560","authenticated-orcid":false,"given":"Gian Franco","family":"Zannoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Angelico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"D\u2019Amati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Scaglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Matias-Guiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Buza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2025.105046_bib1","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/cjp2.184","article-title":"An Analysis of HER2 Amplification in Cervical Adenocarcinoma: Correlation with Clinical Outcomes and the International Endocervical Adenocarcinoma Criteria and Classification","volume":"7","author":"1Shi","year":"2021","journal-title":"J. Pathol. Clin. Res"},{"key":"10.1016\/j.critrevonc.2025.105046_bib2","article-title":"Low-level expression of human Epidermal growth Factor Receptor-2 (HER2) in High-Grade Mullerian Tumors: Implications for therapy decision making","volume":"49","author":"Abada","year":"2023","journal-title":"Gynecol. Oncol. Rep."},{"key":"10.1016\/j.critrevonc.2025.105046_bib3","article-title":"Emerging treatments in HER2-positive advanced breast cancer: Keep raising the bar","volume":"5","author":"Agostinetto","year":"2024","journal-title":"Cell Rep. Med"},{"key":"10.1016\/j.critrevonc.2025.105046_bib4","first-page":"1040","article-title":"Hormonal Environment and HER2 Status in Extra-Mammary Paget's Disease (eMPD): A Systematic Literature Review and Meta-Analysis with Clinical Considerations","volume":"10","author":"Angelico","year":"2020","journal-title":"Diagn. (Basel)"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105046_bib5","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s44276-025-00125-6","article-title":"HER2 amplification and HER2 low expression in endometrial carcinoma: prevalence across molecular, histological and clinicopathological risk groups","volume":"3","author":"Aro","year":"2025","journal-title":"BJC Rep."},{"key":"10.1016\/j.critrevonc.2025.105046_bib6","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/ijgo.13829","article-title":"Immunohistochemical expression of ErbB\/HER family proteins in patients with vulvar cancer","volume":"157","author":"Baiocchi","year":"2022","journal-title":"Int J. Gynaecol. Obstet."},{"key":"10.1016\/j.critrevonc.2025.105046_bib7","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2016.69.4836","article-title":"HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology","volume":"35","author":"Bartley","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105046_bib8","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1136\/ijgc-2020-001771","article-title":"Human epidermal growth factor receptor-2 (HER2) is a potential therapeutic target in extramammary Paget's disease of the vulva","volume":"30","author":"Bartoletti","year":"2020","journal-title":"Int J. Gynecol. Cancer"},{"issue":"3 Pt 1","key":"10.1016\/j.critrevonc.2025.105046_bib9","first-page":"381","article-title":"Expression of epidermal growth factor receptor and HER-2\/neu in normal and neoplastic cervix, vulva, and vagina","volume":"76","author":"Berchuck","year":"1990","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.critrevonc.2025.105046_bib10","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2174\/156800909788166484","article-title":"HER-2 signaling and inhibition in breast cancer","volume":"9","author":"Browne","year":"2009","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.critrevonc.2025.105046_bib11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/PGP.0000000000000711","article-title":"HER2 Testing and Reporting in Endometrial Serous Carcinoma: Practical Recommendations for HER2 Immunohistochemistry and Fluorsecent In Situ Hybridization: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting","volume":"40","author":"Buza","year":"2021","journal-title":"Int J. Gynecol. Pathol."},{"key":"10.1016\/j.critrevonc.2025.105046_bib12","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/modpathol.2013.113","article-title":"Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice","volume":"26","author":"Buza","year":"2013","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.critrevonc.2025.105046_bib13","doi-asserted-by":"crossref","first-page":"687","DOI":"10.5858\/arpa.2020-0207-RA","article-title":"HER2 Testing in Endometrial Serous Carcinoma: Time for Standardized Pathology Practice to Meet the Clinical Demand","volume":"145","author":"Buza","year":"2021","journal-title":"Arch. Pathol. Lab Med"},{"key":"10.1016\/j.critrevonc.2025.105046_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142135","article-title":"Assessment of HER2 Status Using Immunohistochemistry (IHC) and Fluorescence In Situ Hybridization (FISH) Techniques in Mucinous Epithelial Ovarian Cancer: A Comprehensive Comparison between ToGA Biopsy Method and ToGA Surgical Specimen Method","volume":"10","author":"Chao","year":"2015","journal-title":"PLOS ONE"},{"key":"10.1016\/j.critrevonc.2025.105046_bib15","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3390\/genes15070903","article-title":"A Comprehensive Review of HER2 in Cancer Biology and Therapeutics","volume":"15","author":"Cheng","year":"2024","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.critrevonc.2025.105046_bib16","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/his.12090","article-title":"HER2 amplification in squamous cell carcinomas of the vulva","volume":"62","author":"Choschzick","year":"2013","journal-title":"Histopathology"},{"key":"10.1016\/j.critrevonc.2025.105046_bib17","series-title":"Cancer Protocol Templates \u2013 GYN Biomarker Reporting Protocols (version 1.1.0.0, March 2023)","author":"College of American Pathologists","year":"2023"},{"key":"10.1016\/j.critrevonc.2025.105046_bib18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ygyno.2025.02.005","article-title":"HER2 expression in a molecularly defined cohort of endometrial cancer patients: The SPECTRUM study","volume":"194","author":"Cort\u00e9s-Salgado","year":"2025","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105046_bib19","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1200\/JCO.23.02768","article-title":"Clinical and Molecular Characteristics of High-Risk, Recurrent, or Metastatic Endometrial Cancer That Is Human Epidermal Growth Factor Receptor 2-Low","volume":"43","author":"van Dijk","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105046_bib20","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/GCO.0000000000000599","article-title":"Targeting human epidermal growth factor receptor 2 (HER2) in gynecologic malignancies","volume":"32","author":"Erickson","year":"2020","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"10.1016\/j.critrevonc.2025.105046_bib21","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu","volume":"36","author":"Fader","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105046_bib22","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.3390\/cancers13246373","article-title":"The Vulvar Immunohistochemical Panel (VIP) Project: Molecular Profiles of Vulvar Squamous Cell Carcinoma","volume":"13","author":"Garganese","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2025.105046_bib23","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.3390\/cancers15102664","article-title":"HER2 Intratumoral Heterogeneity in Breast Cancer, an Evolving Concept","volume":"15","author":"Hou","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2025.105046_bib24","doi-asserted-by":"crossref","first-page":"935","DOI":"10.3390\/jcm9040935","article-title":"Local and Central Evaluation of HER2 Positivity and Clinical Outcome in Advanced Gastric and Gastroesophageal Cancer-Results from the AGMT GASTRIC-5 Registry","volume":"9","author":"Huemer","year":"2020","journal-title":"J. Clin. Med"},{"key":"10.1016\/j.critrevonc.2025.105046_bib25","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s12253-017-0276-5","article-title":"Discordance Rate of HER2 Status in Primary Gastric Cancer and Synchronous Lymph Node Metastases: Its Impact on Therapeutic Decision and Clinical Management","volume":"24","author":"Ieni","year":"2018","journal-title":"Pathol. Oncol. Res"},{"key":"10.1016\/j.critrevonc.2025.105046_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0257976","article-title":"Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis","volume":"16","author":"Itkin","year":"2021","journal-title":"PLoS One"},{"issue":"43","key":"10.1016\/j.critrevonc.2025.105046_bib27","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_390772","article-title":"Antibody-Drug Conjugates in Gynecologic Cancer","author":"Karpel","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.critrevonc.2025.105046_bib28","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00428-023-03640-4","article-title":"HER2 status as a potential predictive biomarker for ovarian clear cell carcinoma","volume":"483","author":"Kendall B\u00e1rt\u016f","year":"2023","journal-title":"Virchows Arch."},{"key":"10.1016\/j.critrevonc.2025.105046_bib29","doi-asserted-by":"crossref","first-page":"7992","DOI":"10.1038\/s41598-024-57515-y","article-title":"Human Epidermal Growth Factor Receptor-2 Expression and Subsequent Dynamic Changes in Patients with Ovarian Cancer","volume":"14","author":"Kim","year":"2024","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105046_bib30","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ygyno.2022.09.006","article-title":"HER2 in Uterine Serous Carcinoma: Testing platforms and implications for targeted therapy","volume":"167","author":"Klc","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105046_bib31","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s13058-024-01911-9","article-title":"Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295h\u2009+\u2009HER2- breast cancer: a retrospective analysis","volume":"26","author":"Kook","year":"2024","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.critrevonc.2025.105046_bib32","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/his.13704","article-title":"HER2 immunohistochemistry in endometrial and ovarian clear cell carcinoma: discordance between antibodies and with in-situ hybridisation","volume":"73","author":"Koopman","year":"2018","journal-title":"Histopathology"},{"key":"10.1016\/j.critrevonc.2025.105046_bib33","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ygyno.2004.01.006","article-title":"Expression of HER2neu (c-erbB-2) and Epidermal Growth Factor Receptor in Cervical Cancer: Prognostic Correlation with Clinical Characteristics, and Comparison of Manual and Automated Imaging Analysis","volume":"93","author":"Lee","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105046_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0191972","article-title":"The Prognostic Value of HER2 in Ovarian Cancer: A Meta-Analysis of Observational Studies","volume":"13","author":"Luo","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2025.105046_bib35","doi-asserted-by":"crossref","DOI":"10.1097\/PAS.0000000000002392","article-title":"Comparison of HER2 Scoring Systems in Endometrial Cancer: Toward Optimization of HER2-Directed Therapies","author":"Menshikova","year":"2025","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.critrevonc.2025.105046_bib36","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105046_bib37","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105046_bib38","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/PAP.0000000000000458","article-title":"The Role of Predictive and Prognostic Biomarkers in Lower Female Genital Tract Pathology: PD-L1, MMR, HER2, p16, p53, and Beyond","volume":"32","author":"Mills","year":"2025","journal-title":"Adv. Anat. Pathol."},{"key":"10.1016\/j.critrevonc.2025.105046_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yexcr.2018.08.009","article-title":"Epidermal growth factor receptor: Structure-function informing the design of anticancer therapeutics","volume":"371","author":"Mitchell","year":"2018","journal-title":"Exp. Cell Res"},{"key":"10.1016\/j.critrevonc.2025.105046_bib40","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105046_bib41","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1186\/s12935-022-02761-1","article-title":"HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry","volume":"22","author":"Morsberger","year":"2022","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.critrevonc.2025.105046_bib42","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1200\/JCO.22.02558","article-title":"Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2-Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial","volume":"41","author":"Nishikawa","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105046_bib43","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.gene.2005.10.018","article-title":"Epidermal growth factor receptor (EGFR) signaling in cancer","volume":"366","author":"Normanno","year":"2006","journal-title":"Gene"},{"key":"10.1016\/j.critrevonc.2025.105046_bib44","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s11912-023-01434-0","volume":"25","author":"P\u00e9rez","year":"2023","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.critrevonc.2025.105046_bib45","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.3390\/cancers16112100","article-title":"Implementation of HER2 Testing in Endometrial Cancer, a Summary of Real-World Initial Experience in a Large Tertiary Cancer Center","volume":"16","author":"Plotkin","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2025.105046_bib46","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ygyno.2004.06.048","article-title":"The prognostic and predictive value of immunohistochemically detected HER-2\/neu overexpression in 361 patients with ovarian cancer: a multicenter study","volume":"95","author":"Riener","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105046_bib47","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41379-020-00695-5","article-title":"Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assays","volume":"34","author":"Robinson","year":"2021","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.critrevonc.2025.105046_bib48","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/s41379-021-00997-2","article-title":"Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas","volume":"3","author":"Ross","year":"2022","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.critrevonc.2025.105046_bib49","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1006\/scbi.1998.0083","article-title":"The HER-2\/neu oncogene: prognostic factor, predictive factor and target for therapy","volume":"9","author":"Ross","year":"1999","journal-title":"Semin Cancer Biol."},{"key":"10.1016\/j.critrevonc.2025.105046_bib50","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S0002-9378(12)90907-2","article-title":"Prognostic significance of HER-2\/neu expression in advanced epithelial ovarian cancer: a multivariate analysis","volume":"168","author":"Rubin","year":"1993","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.critrevonc.2025.105046_bib51","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.3390\/ijms25021064","article-title":"Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various Cancers","volume":"25","author":"Rubin","year":"2024","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2025.105046_bib52","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2174\/1568026620666200303123102","article-title":"Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors","volume":"20","author":"Sabbah","year":"2020","journal-title":"Curr. Top. Med Chem."},{"key":"10.1016\/j.critrevonc.2025.105046_bib53","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ygyno.2025.03.012","article-title":"Distribution and concordance of HER2 scores in endometrial and ovarian cancer","volume":"195","author":"Salinaro","year":"2025","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105046_bib54","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.3390\/cancers13112623","article-title":"New Pathological and Clinical Insights in Endometrial Cancer in View of the Updated ESGO\/ESTRO\/ESP Guidelines","volume":"13","author":"Santoro","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2025.105046_bib55","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00428-019-02528-6","article-title":"Comprehensive analysis of PD-L1 expression, HER2 amplification, ALK\/EML4 fusion, and mismatch repair deficiency as putative predictive and prognostic factors in ovarian carcinoma","volume":"474","author":"Schmoeckel","year":"2019","journal-title":"Virchows Arch."},{"key":"10.1016\/j.critrevonc.2025.105046_bib56","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: advances and future directions","volume":"22","author":"Swain","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.critrevonc.2025.105046_bib57","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.3390\/cancers16051062","article-title":"High HER2 Intratumoral Heterogeneity Is a Predictive Factor for Poor Prognosis in Early-Stage and Locally Advanced HER2-Positive Breast Cancer","volume":"16","author":"Tanei","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2025.105046_bib58","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00428-021-03034-4","article-title":"Assessment of HER2 using the 2018 ASCO\/CAP guideline update for invasive breast cancer: a critical look at cases classified as HER2 2+ by immunohistochemistry","volume":"479","author":"Taylor","year":"2021","journal-title":"Virchows Arch."},{"key":"10.1016\/j.critrevonc.2025.105046_bib59","article-title":"RT-qPCR is helpful to distinguish the clinicopathological features of HER2 immunohistochemistry 0 and 1","volume":"247","author":"Yue","year":"2023","journal-title":"Pathol. Res Pr."},{"key":"10.1016\/j.critrevonc.2025.105046_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.925551","article-title":"Get al. Case Report: Prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin","volume":"12","author":"Zattarin","year":"2022","journal-title":"Front Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825004342?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825004342?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T12:40:41Z","timestamp":1770036041000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825004342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":60,"alternative-id":["S1040842825004342"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105046","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HER2 in gynecological malignancies: Bridging the gap between standardized pathological assessment and precision therapy","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105046"}}